Merging Yamanouchi and Fujisawa to create Astellas (2005)

Why the third and fifth firms staged an “equal merger” under a new name

Japan’s pharmaceutical industry had, by the early 2000s, run out of room to grow at home: official prices were cut every two years, while the cost of discovering a drug kept rising and the Western majors kept combining to pay for it. Yamanouchi and Fujisawa were third and fifth in the domestic market — large enough to matter, too small to fund discovery on the scale that was becoming standard. What made the pairing work was that they did not compete: urology and cardiovascular medicine on one side, transplantation and immunology on the other. The deal was presented as a merger of equals under an entirely new name, with divisional heads drawn from both companies, and that presentation was itself part of the design — a firm assembled from two proud research cultures had to give neither the standing of the acquired.

What it bought was scale of a specific kind. Roughly ¥800 billion of drug sales, 2,400 sales representatives and, above all, an R&D budget of ¥145 billion — past the threshold then regarded as the entry price for global competition. But scale alone settled nothing. Within three years the development headquarters had moved to the United States, and within five the company had spent about ¥370 billion on OSI Pharmaceuticals. The merger did not solve the pipeline problem; it created a balance sheet large enough to keep buying solutions to it, which is the pattern the next twenty years follow.